Ramucirumab for Patients with AFP-High Hepatocellular Carcinoma Granted FDA Approval – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Officials with the FDA have approved ramucirumab (Cyramza, Eli Lilly and Company) as a single agent in certain patients with hepatocellular carcinoma (HCC), according to a press release. Patients with HCC who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib are eligible for this treatment.1
Approximately half of all patients with advanced HCC are AFP-high and these patients have a poor prognosis relative to the general HCC patient population, according to Eli Lilly.2 Despite recent advancements in treating HCC, there has been an unmet need for patients in this treatment setting.